Navigation Links
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012

INCLINE VILLAGE, Nev., Sept. 18 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the "Notes"). The conversion rate, as adjusted, is 94.447 shares of common stock per $1,000 principal amount of the Notes, effective September 18, 2009. The conversion rate for the Notes was previously 89.165 shares of common stock per $1,000 principal amount of the Notes.

On March 2, 2009, PDL announced a cash dividend of $0.50 per share of its common stock, payable to stockholders of record on September 17, 2009. In connection with the cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding September 15, 2009, the ex-dividend date for the cash dividend, and the denominator of which is the difference of such average closing price less $0.50.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering
2. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
3. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
4. Helix BioPharma Closes Private Placement
5. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
6. Helix BioPharma Announces $13.5 Million Private Placement
7. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
8. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
9. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
10. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... Mass. and TORONTO , Oct. ... GNBT) today announced that it has entered into a non-binding ... ), a private Israeli company that has developed a proprietary ... infertile due to varicoceles. the United States ... between the ages of 25 and 44 diagnosed ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... personalized medicine, is excited to announce their partnership with the Keck Medicine ... genetics of chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
Breaking Biology News(10 mins):